1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

15 Feb 2021
Admin
News Article

Us Fda Clears Lysogenes Ind Application To Initiate Gene Therapy Clinical Trial With Lys-Gm101 To Treat Gm1 Gangliosidosis

Lysogene Announced That The Us Food And Drug Administration (Fda) Has Cleared Its Investigational New Drug (Ind) Application For Lys-Gm101, The Company&Rsquo;S Gene Therapy Candidate For The Treatment Of Gm1 Gangliosidosis, A Serious, Pediatric, Life Threatening Disease. Lys-Gm101 Builds On Lysogene&Rsquo;S Extensive Experience In Direct To Cns Adeno-Associated Viral Vector (Aav)-Based Gene Therapy Clinical Development.The Ind Clearance Follows The Recent Clinical Trial Authorization Granted By The Mhra In The United Kingdom. Lysogene Intends To Initiate Its Global, Multi-Center, Single-Arm, And Two-Stage, Adaptive-Design Clinical Trial Of Lys-Gm101 In Patients With A Diagnosis Of Early Or Late Infantile Gm1 Gangliosidosis. The Clinical Trial Will Include A Safety Phase And A Confirmatory Efficacy Phase. The Company Intends To Dose A Total Of 16 Patients, With Dosage Of The First Patient Expected In The First Half Of 2021.&Ldquo;We Are Very Pleased To Receive This Ind Clearance For Lys-Gm101 Which Completes The Mhra Approval Received A Few Weeks Ago. It Represents A Major Milestone That Marks Our Second Cns Gene-Therapy Program To Enter Into A Global Clinical Trial&Rdquo; Said Karen Aiach, Founder Chairman And Chief Executive Officer Of Lysogene. &Ldquo;This Ind Clearance Once Again Demonstrates Our Quality And Timely Execution, And Our Strong Determination To Bring New Therapeutic Solutions For Diseases That Currently Have No Treatment.&Rdquo;Christine Waggoner, President And Co-Founder Of Cure Gm1 Foundation Added: &Ldquo;Children With Gm1 Gangliosidosis Represent A Clear Unmet Medical Need And We Are Thrilled To See A New Therapeutic Option Entering The Clinic, As It Brings Tremendous Hope To Families And The Entire Gm1 Gangliosidosis Community.&Rdquo;Lys-Gm101 (&Lsquo;Adeno-Associated Viral Vector Serotype Rh.10 Expressing Beta-Galactosidase&Rsquo;) Received Orphan Drug Designation For The Treatment Of Gm1 Gangliosidosis In The European Union And In The Us In 2017, As Well As Rare Pediatric Disease Designation In The Us In 2016.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!